TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 Antimicrobial Resistance Threats Report classifies 19 pathogens as urgent, serious or concerning threats and lists six more for monitoring. Together, the pathogens are estimated to cause 9.7 million infections and 50,800 deaths in the United States each year.
The CDC’s updated 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens as urgent, serious or concerning threats and places six others on a watch list. The agency estimates that the pathogens collectively cause 9.7 million U.S. infections and 50,800 deaths annually, underscoring the ongoing health burden from infections that are difficult to treat with available drugs.
Four drug-resistant pathogens are in the report’s top-tier urgent threat category: Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The CDC report groups these pathogens among those requiring aggressive action, though the supplied material does not provide a single combined death count for the four.
The report gives several 2023 figures for specific pathogens. Carbapenem-resistant Acinetobacter was linked to 9,497 U.S. hospitalizations and an estimated 817 deaths that year. Carbapenem-resistant Enterobacterales was linked to 14,878 hospitalizations and an estimated 1,252 deaths. The CDC also estimated that drug-resistant N. gonorrhoeae caused 787,000 infections in 2023; 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or had elevated minimum inhibitory concentrations.
Other changes include drug-resistant N. meningitidis moving into the serious-threat category and drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria joining the watch list. Clostridioides difficile moved down from urgent to serious. The report says infection-prevention efforts have helped reduce C. difficile cases since 2011.
The Burden on Patients and Care
Antimicrobial resistance can make infections harder to treat and leave clinicians with fewer effective options. The consequences extend beyond the infection itself: the Infectious Diseases Society of America says resistant infections can prolong hospital stays and increase health care costs. They may also complicate care that depends on preventing or managing infection, including cancer chemotherapy, organ transplants and surgery.
The report’s aggregate estimate—50,800 deaths per year—puts the scale of the problem in public-health terms, while the pathogen-specific figures show how the burden varies. Some infections are associated with hospitals and nursing homes, while gonorrhea is a sexually transmitted infection. Those differences matter for prevention, testing and treatment; the figures should not be read as meaning that every infection has the same risk or outcome.
In a statement cited by MedPage Today, IDSA president Wendy Armstrong said resistant infections affect patients as well as health systems, and urged Congress to act on the PASTEUR Act. The proposal would create a federal program to support development of antimicrobial drugs targeting serious infections. According to the source report, versions of the bill remain stalled in congressional committees.
Products Worth Considering
Levoit Eleva 300X HEPA Air Purifier for Home and Bedroom
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
How the CDC Revised Its Threat List
The CDC’s report sorts pathogens by assessed threat level, from concerning and serious to urgent, and separately identifies organisms on a watch list. The watch list includes potential threats for which the disease burden is uncertain, according to the source material. Its inclusion is a signal for monitoring, not a statement that each listed pathogen currently causes a known level of illness or death.
Some of the report’s figures describe different time periods and measures. For example, reported U.S. C. auris cases rose from 48 in 2016, when the pathogen was first reported in the country, to 4,523 in 2023. That is a case count comparison, not an estimate of annual deaths. The report also notes that most 2023 carbapenem-resistant Acinetobacter cases began outside hospitals, even though the organism is a particular concern in hospitals and nursing homes.
For gonorrhea, the source says the FDA approved gepotidacin (Blujepa) and zoliflodacin (Nuzolvence) in 2025 as the first new antibiotics for the infection in decades. The CDC’s revised assessment arrives amid concern that resistance can narrow treatment choices, but the supplied report does not state that these drugs resolve the wider resistance problem.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Published Estimates
The source material reports the CDC’s combined annual estimate but does not give the underlying calculation, confidence ranges or a year-by-year trend for the 9.7 million infections and 50,800 deaths. It is also not clear from the supplied details how much of the total is attributable to each pathogen, or how the estimate divides deaths among the 19 categorized threats and six watch-list organisms.
Several pathogen-specific figures are explicitly for 2023, while the total is presented as an annual estimate. The categories describe assessed threat levels, not individual patient outcomes. The source material also does not provide detailed criteria for each category or the expected timetable for future updates. Those details would be needed to compare the report’s estimates directly with other years or to determine how much the burden has changed overall.
Policy and Surveillance Ahead
The CDC’s updated list directs attention to pathogens it considers urgent or serious and to emerging organisms whose burden remains uncertain. Continued surveillance will be needed to track infections, resistance patterns and whether prevention measures—including those associated with lower C. difficile case numbers—are changing outcomes.
On the policy front, Armstrong called for passage of the PASTEUR Act, which would establish federal support for developing antimicrobial drugs. The source report says the bill’s versions remain in congressional committees; it does not identify a vote date or a next legislative milestone. The timing of any action is therefore unclear.
Key Questions
What does the CDC estimate these pathogens cause each year?
The CDC estimates that the pathogens in the updated report cause 9.7 million infections and 50,800 deaths annually in the United States. The supplied material does not give a breakdown of that combined estimate by pathogen.
Which pathogens are listed as urgent threats?
The four urgent drug-resistant pathogens named in the report are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower threat category?
The report moved Clostridioides difficile from urgent to serious and says successful infection-prevention measures have helped reduce case numbers since 2011.
What is the CDC watch list?
The watch list contains pathogens the agency identifies as potential threats, including organisms with an uncertain disease burden. The source names drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria among the additions.
What is the PASTEUR Act?
It is proposed federal legislation that, according to the source report, would create a program to support development of antimicrobial drugs against threatening pathogens and infections. The report says versions of the bill remain stalled in congressional committees.
Source: medpagetoday.com
